Aura Biosciences’ (AURA) “Buy” Rating Reaffirmed at HC Wainwright

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 194.12% from the stock’s previous close.

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $7.48 on Monday. The firm has a 50-day moving average of $7.66 and a 200-day moving average of $8.67. The stock has a market cap of $373.63 million, a PE ratio of -4.32 and a beta of 0.30. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 23,045 shares of company stock worth $177,242. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new position in Aura Biosciences in the 4th quarter valued at approximately $127,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Aura Biosciences by 27.7% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,516 shares of the company’s stock valued at $1,122,000 after acquiring an additional 29,618 shares during the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Aura Biosciences by 43.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after acquiring an additional 118,000 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Aura Biosciences by 56.7% during the fourth quarter. Deutsche Bank AG now owns 44,085 shares of the company’s stock valued at $362,000 after acquiring an additional 15,951 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Aura Biosciences by 20.5% during the fourth quarter. Bank of America Corp DE now owns 51,286 shares of the company’s stock valued at $422,000 after acquiring an additional 8,709 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.